NCT05231044 - A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

November 20, 2023

Study Completion Date

November 20, 2023

Conditions

Actinic Keratosis

Interventions

DRUG

KX01 ointment 1%

The experimental drug, KX01 Ointment 1% is used in participants with Clinically typical AK on the face or scalp.

DRUG

Placebo

Vehicle Ointment is used in participants with Clinically typical AK on the face or scalp.

Trial Locations (20)

Toho University Medical Center Sakura Hospital, Chiba

Kiryu Dermatology Clinic, Fukuoka

Tomoko Matsuda dermatology Clinic, Fukuoka

Takamatsu Red Cross Hospital, Kagawa

Hashiguchi Dermatology, Kagoshima

Katahira Dermatology and Urology, Kagoshima

National Hospital Organization Sagamihara National Hospital, Kanagawa

Nippon Medical School Musashi Kosugi Hospital, Kanagawa

Kumamoto University Hospital, Kumamoto

Noguchi Dermatology Clinic, Kumamoto

Suizenji Dermatology Clinic, Kumamoto

Futaba Dermatology and Skin Surgery Clinic, Miyazaki

Toyama Hifuka, Miyazaki

Okayama Saiseikai Outpatient Center Hospital, Okayama

Medical Corporation Ayumi Sakurakai Dermatology Ophthalmology Kume Clinic, Osaka

Mochidahifuka, Osaka

Juntendo University Hospital, Tokyo

NTT Medical Center Tokyo, Tokyo

Toyama Prefectural Central Hospital, Toyama

University of Yamanashi Hospital, Yamanashi